

Modern HIV medications are powerful in both managing the infection and preventing its transmission and many of its…

As the Network moves into its second year of operations, with our Regional Teams and scientific Think Tanks…

Led by Dr. Darrell Tan and supported by the CTN+, this document provides the most update-to-date evidence for…
Randomized Trial to Prevent Vascular Events in HIV REPRIEVE is the first large-scale randomized clinical research trial to test a strategy for heart disease prevention among people living with HIV. Specifically, REPRIEVE will test whether a daily dose of a statin (pitavastatin) reduces the risk of heart disease among people living with HIV.
CTN+ Researchers are the backbone of the Network through generating ideas, collaborating on new initiatives, conducting research, and sharing their knowledge.
Explore Our NetworkInterested in joining the CTN+? We’re always on the lookout for new members to answer the most pressing research questions of today, while anticipating the questions of tomorrow.
Learn More